Showing posts from July, 2024Show all
health-issue
Press Release: Online availability of Sanofi’s half-year financial report for 2024
https://ift.tt/xwIQYg6 Online availability of Sanofi’s half-year financial report for 2024 from Sanofi - Aventis Groupe https://ift.tt/ydsvDL4 vi…
Read more
health-issue
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
https://ift.tt/FDUSs3t Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded from Sanofi - Aventis Groupe https://ift.tt/cVF…
Read more
health-issue
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
https://ift.tt/zPEl2I3 from Sanofi - Aventis Groupe https://ift.tt/qvjxlhr via IFTTT
Read more
health-issue
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
https://ift.tt/PzQ59md Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD from Sanofi - Aventis Groupe https://…
Read more
health-issue
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
https://ift.tt/PzQ59md Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD from Sanofi - Aventis Groupe https://…
Read more
